<DOC>
	<DOCNO>NCT00974896</DOCNO>
	<brief_summary>To assess safety , tolerability , pharmacokinetic profile AMG 479 use combination bevacizumab , sorafenib , panitumumab , erlotinib , gemcitabine subject advance solid tumor . Up 126 subject may enrol . Sorafenib erlotinib combo cohort enrol . All combo cohort close enrollment .</brief_summary>
	<brief_title>QUILT-2.016 : Study AMG 479 With Biologics Chemotherapy Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Competent comprehend , sign , date Institutional Review Board ( IRB ) approve informed consent form Men woman ≥ 18 year old pathologically cytologically document , advance solid tumor refractory least one line therapy standard therapy available curative therapy available , subject refuse standard noncurative therapy Measurable disease evaluable disease per World Health Organization ( WHO ) guideline Eastern Cooperative Oncology Group performance status ≤ 2 Life expectancy 3 month document investigator Adequate hematologic , renal hepatic function Any comorbid medical condition would increase risk toxicity opinion Investigator Sponsor Unresolved toxicity prior anticancer therapy , define resolved Common Terminology Criteria Adverse Events ( CTCAE ) grade 0 1 , level dictate inclusion/exclusion criterion exception alopecia Subjects primary metastatic central nervous system ( CNS ) tumor allow enroll sorafenib cohort . These subject allow enroll remain cohort , CNS tumor control prior surgery radiation , neurologically stable History lymphoma , leukemia , highdose chemotherapy hematopoietic stem cell rescue Uncontrolled hypertension [ diastolic &gt; 100 mmHg systolic &gt; 150 mmHg ] ; Subjects enrol sorafenib group must diastolic &gt; 85 mmHg systolic &gt; 145 mmHg Clinically significant ECG change obscure ability ass PR , QT , QRS interval Presence ascites pleural effusion require chronic medical intervention Diagnosis arterial venous thrombosis within 6 month enrollment ; history bleed diathesis History clinically significant hypoglycemia hyperglycemia opinion investigator Myocardial infarction within 6 month enrollment , symptomatic congestive heart failure ( New York Heart Association &gt; class II ) , unstable angina , unstable cardiac arrhythmia require medication Active peptic ulcer disease History chronic hepatitis Subject know test positive HIV Known sensitivity mammalian derive product Hematological function , follow : Absolute neutrophil count ( ANC ) ≤ 1.5 x 109/L B , P , S E cohort Absolute neutrophil count ( ANC ) ≤ 3 x 109/L G cohort Platelet count ≤ 100 x 109/L Hemoglobin ≤ 9 g/dL Renal function , follow : Calculated creatinine clearance &lt; 50 ml/min use modify CockroftGault equation Urinary protein quantitative value &gt; 30 mg &gt; 1+ dipstick , unless quantitative protein &lt; 500 mg 24 hour urine sample Hepatic function , follow : Aspartate aminotransferase ( AST ) &gt; 2.5 x upper limit normal ( ULN ) ( liver metastasis present , ≥ 5 x ULN ) Alanine aminotransferase ( ALT ) &gt; 2.5 x ULN ( liver metastasis present , ≥ 5 x ULN ) Alkaline phosphatase &gt; 2.0 x ULN ( bone liver metastases present , ≥ 5 x ULN ) Bilirubin &gt; 2.0 x ULN Prothrombin time ( PT ) partial thromboplastin time ( PTT ) &gt; 1.5 x ULN Treatment anticancer therapy ( 6 week nitrosoureas mitomycin C chemotherapy ) , antibody therapy , retinoid therapy , hormonal therapy within 4 week study day 1 . Prior concurrent use hormone replacement therapy use gonadotropinreleasing hormone ( GnRH ) modulators prostate cancer permit Therapeutic palliative radiation therapy within 4 week enrollment ( subject must resolution significant adverse effect radiation therapy receive prior 2 week enrollment ) Concurrent prior ( within 1 week study Day 1 ) anticoagulation therapy , except lowdose warfarin ( ≤ 2 mg/day ) prophylaxis central venous catheter thrombosis Prior participation clinical drug trial within 4 week enrollment For subject receive erlotinib , use ketoconazole , clarithromycin , voriconazole , troleandomycin , telithromycin , rifabutin , rifapentine , phenytoin , carbamazepine , phenobarbital St. John 's Wort prohibit For subject receive sorafenib , use St. John 's Wort , rifampin , phenytoin , carbamazepine , dexamethasone , phenobarbital ( CYP3A inducer ) prohibit Type 1 2 diabetic exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>AMG 479</keyword>
	<keyword>Amgen</keyword>
	<keyword>Oncology</keyword>
	<keyword>Phase 1b</keyword>
</DOC>